The natural history of treated Parkinson's disease in an incident, community based cohort
- 30 September 2011
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 82 (10), 1112-1118
- https://doi.org/10.1136/jnnp.2011.240366
Abstract
Background Our understanding of the natural history of idiopathic Parkinson's disease (PD) remains limited. In the era of potential disease modifying therapies, there is an urgent need for studies assessing the natural evolution of treated PD from onset so that relevant outcome measures can be identified for clinical trials. No previous studies have charted progression in unselected patients followed from the point of diagnosis. Methods A representative cohort of 132 PD patients was followed from diagnosis for up to 7.9 years (mean 5.2 years). Comprehensive clinical and neuropsychological evaluations were performed every 18 months. Disease progression was evaluated using well validated clinical measures (motor progression and development of dyskinesia on the Unified PD Rating Scale and Hoehn-Yahr scale, dementia onset according to DSM-IV criteria). Multi-level linear modelling was used to chart the nature and rate of progression in parkinsonian symptoms and signs over time. The prognostic importance of baseline demographic, clinical and genetic variables was evaluated using survival analysis. Results Axial (gait and postural) symptoms evolve more rapidly than other motor features of PD and appear to be the best index of disease progression. Conversely, conventional outcome measures are relatively insensitive to change over time. Earlier onset of postural instability (Hoehn-Yahr stage 3) is strongly associated with increased age at disease onset and has a significant impact on quality of life. Conclusions Dementia risk is associated with increased age, impaired baseline semantic fluency and the MAPT H1/H1 genotype. The efficacy of disease modifying therapies may be more meaningfully assessed in terms of their effects in delaying the major milestones of PD, such as postural instability and dementia, since it is these that have the greatest impact on patients.Keywords
This publication has 21 references indexed in Scilit:
- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's DiseaseThe New England Journal of Medicine, 2009
- Comparative responsiveness of Parkinson's disease scales to change over timeMovement Disorders, 2009
- UPDRS activity of daily living score as a marker of Parkinson's disease progressionMovement Disorders, 2008
- Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's diseaseAnnals of Neurology, 2007
- Rate of clinical progression in Parkinson's disease. A prospective studyMovement Disorders, 2007
- Longitudinal study of the motor response to levodopa in Parkinson's diseaseMovement Disorders, 2006
- Neuropathology of dementia in Parkinson's disease: A prospective, community‐based studyAnnals of Neurology, 2005
- Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 yearsMovement Disorders, 2004
- Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's diseaseMovement Disorders, 2004
- A Meta-Analytic Review of Verbal Fluency Performance Following Focal Cortical Lesions.Neuropsychology, 2004